Skip to content
PIL Logo

Colistimethate Sodium 1 Million I.U. Powder for Solution for Injection

Last Updated on eMC 10-Aug-2016 View document  | Beacon Pharmaceuticals Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 10-Aug-2016 and displayed until Current

Reasons for adding or updating:

  • Change to section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 3 - dose and frequency
  • Change to section 6 - date of revision

Updated on 30-Mar-2011 and displayed until 10-Aug-2016

Reasons for adding or updating:

  • Change to information for healthcare professionals
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to dosage and administration

Updated on 18-Oct-2010 and displayed until 30-Mar-2011

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 29-Jul-2010 and displayed until 18-Oct-2010

Reasons for adding or updating:

  • New PIL for new product

Company contact details

Beacon Pharmaceuticals

Company image
Address

85 High Street, Tunbridge Wells, TN1 1YG

Fax

0845 437 5567

Medical Information e-mail
Telephone

0845 437 5565

Medical Information Direct Line

+44 (0)1233 506 574

Customer Care direct line

0800 220 280

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

colistimethate sodium

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue